Browse by category

SELECT: Semaglutide reduces CV events in non-diabetic patients with overweight or obesity

Semaglutide 2.4mg (Wegovy) reduces cardiovascular events in patients with overweight or obesity and pre-existing cardiovascular disease...

Preoperative antihypertensive drugs and visceral fat area can predict hypertension remission and recurrence post-LSG

7 days ago

Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss

7 days ago

Racial and ethnic groups face barriers to obtaining OMMs

7 days ago

Weekly Digest